Previous 10 | Next 10 |
Longer term follow-up data from the pivotal CARTITUDE-1 study of cilta-cel in heavily pretreated patients with relapsed or refractory multiple myeloma The first presentation of data from the CARTITUDE-2 study of cilta-cel in earlier lines of multiple myeloma treatment ...
CANbridge will make a $10 million upfront payment for the two Fabry and Pompe candidates. Guangzhou Link Health Pharma and Australia's George Clinical plan to form a China clinical CRO JV that will conduct trials for Link Health's in-licensed portfolio. Discovered by CStone's part...
Submission follows accelerated assessment granted by the Committee for Medicinal Products for Human Use of the European Medicines Agency of the application based on positive Phase 1b/2 CARTITUDE-1 study data Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech...
Legend Biotech Corporation (LEGN) Q4 2020 Earnings Conference Call March 18, 2021 08:00 AM ET Company Participants Jessie Yeung - Head of Corporate Finance & Investor Relations Ying Huang - Chief Executive Officer & Chief Financial Officer Conference Call Participants Matthew Harrison...
The following slide deck was published by Legend Biotech Corporation in conjunction with their 2020 Q4 earnings call. For further details see: Legend Biotech Corporation 2020 Q4 - Results - Earnings Call Presentation
Legend Biotech (LEGN): Q4 GAAP EPS of -$0.22 beats by $0.08.Revenue of $40.78M (+109.7% Y/Y) beats by $28.78M.Press Release For further details see: Legend Biotech EPS beats by $0.08, beats on revenue
Legend received approximately $659.8 million in gross proceeds through share capital increases during 2020, including a successful Nasdaq IPO with aggregate gross proceeds of $487.3 million. U.S. FDA clearance for IND application for a Phase 1 clinical trial to evaluate LB1901 in ...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will release its fourth quarter and full-year 2020 financial...
Legend Biotech ([[LEGN]] +1.2%) announces preliminary, unaudited financial results for the year ended December 31, 2020. Company expects to record a loss for the year of ~$292.2M to $324.9M and an adjusted loss for the year of ~$202.4M to $234.4M.Research and development expenses of ~$220.7M ...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today in conjunction with an announcement to be issued by Legend Biotech...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...